Literature DB >> 22682762

Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain.

Murat Civaner1.   

Abstract

OBJECTIVE: This study aimed to examine the types of sales strategies used by pharmaceutical companies in a "pharmerging" market and to gain insight into the ways of avoiding the negative effects of these strategies.
METHOD: In-depth interviews were conducted with 22 physicians and company employees in the six largest cities of Turkey. The interviews were analyzed using content analysis.
RESULTS: Various sales strategies, both legal and illegal, are universally applied. These methods target prescribers, patients, pharmacists, and society in general. Different types of companies, organizations, professionals, and science and ethical principles are used as means. Companies intervene immediately to prevent developments that may decrease sales, and exploit the educational and infrastructural needs. In contrast, physicians are overconfident about the effects of marketing and insufficiently educated on how to cope with the strategies and the drugs on the market, which make them vulnerable. Under these conditions, along with worldwide competition and economic volatility, policies that aim to set frameworks for pharmaceutical relationships have failed.
CONCLUSION: Interventions are crucial, including instituting a national drug policy, minimizing the exposure to marketing, and addressing the educational and infrastructural needs of the prescribers. Without these interventions, gaps will continue to be exploited by companies for their own advantage, and the problems related to marketing will persist.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22682762     DOI: 10.1016/j.healthpol.2012.05.006

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  9 in total

1.  Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.

Authors:  Moliehi Matlala; Andries G S Gous; Johanna C Meyer; Brian Godman
Journal:  Front Pharmacol       Date:  2020-08-18       Impact factor: 5.810

Review 2.  Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.

Authors:  Brian Godman; Bjorn Wettermark; Menno van Woerkom; Jessica Fraeyman; Samantha Alvarez-Madrazo; Christian Berg; Iain Bishop; Anna Bucsics; Stephen Campbell; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Harald Herholz; Marija Kalaba; Ott Laius; Jutta Piessnegger; Catherine Sermet; Ulrich Schwabe; Vera V Vlahović-Palčevski; Vanda Markovic-Pekovic; Luka Vončina; Kamila Malinowska; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-17       Impact factor: 5.810

Review 3.  Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.

Authors:  Brian Godman; Rickard E Malmström; Eduardo Diogene; Sisira Jayathissa; Stuart McTaggart; Thomas Cars; Samantha Alvarez-Madrazo; Christoph Baumgärtel; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Irene Eriksson; Alexander Finlayson; Jurij Fürst; Kristina Garuoliene; Iñaki Gutiérrez-Ibarluzea; Krystyna Hviding; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Kamila Malinowska; Hanne B Pedersen; Vanda Markovic-Pekovic; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Susan Spillane; Dominik Tomek; Luka Vončina; Vera Vlahović-Palčevski; Janet Wale; Magdalena Wladysiuk; Menno van Woerkom; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-10       Impact factor: 5.810

4.  Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Lays P Marra; Vania E Araújo; Thales B C Silva; Leonardo M Diniz; Augusto A Guerra Junior; Francisco A Acurcio; Brian Godman; Juliana Álvares
Journal:  Diabetes Ther       Date:  2016-04-05       Impact factor: 2.945

5.  Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications.

Authors:  Qamar Niaz; Brian Godman; Stephen Campbell; Dan Kibuule
Journal:  Int J Clin Pharm       Date:  2020-05-26

6.  Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wânia Cristina da Silva; Vânia Eloisa de Araujo; Ellias Magalhães E Abreu Lima; Jessica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Paulo Henrique Ribeiro Fernandes Almeida; Francisco de Assis Acurcio; Brian Godman; Amanj Kurdi; Mariângela Leal Cherchiglia; Eli Iola Gurgel Andrade
Journal:  BioDrugs       Date:  2018-12       Impact factor: 5.807

7.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

8.  Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

Authors:  Winnie de Bruijn; Cristina Ibáñez; Pia Frisk; Hanne Bak Pedersen; Ali Alkan; Patricia Vella Bonanno; Ljiljana S Brkičić; Anna Bucsics; Guillaume Dedet; Jaran Eriksen; Joseph O Fadare; Jurij Fürst; Gisselle Gallego; Isabella P Godói; Augusto A Guerra Júnior; Hakkı Gürsöz; Saira Jan; Jan Jones; Roberta Joppi; Saim Kerman; Ott Laius; Newman Madzikwa; Einar Magnússon; Mojca Maticic; Vanda Markovic-Pekovic; Amos Massele; Olayinka Ogunleye; Aisling O'Leary; Jutta Piessnegger; Catherine Sermet; Steven Simoens; Celda Tiroyakgosi; Ilse Truter; Magnus Thyberg; Kristina Tomekova; Magdalena Wladysiuk; Sotiris Vandoros; Elif H Vural; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-07-22       Impact factor: 5.810

9.  A follow-up study on the effects of an educational intervention against pharmaceutical promotion.

Authors:  M Murat Civaner
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.